Philip Vorwald has been appointed vice president and general manager of Celsis International’s In Vitro Technologies (Celsis IVT) division. He will be responsible for setting and overseeing the long-term growth strategy of the company’s ADME-Tox products, which include fresh and cryopreserved cells, enzymes and other media produced for drug development. He will report to Jay LeCoque, Celsis International’s chief executive officer.

“Philip’s extensive life science, international management and business development experience will prove integral in the growth of Celsis IVT,” said Mr. LeCoque. “I’m confident that with Phil’s leadership, Celsis IVT will significantly expand its presence in the ADME-Tox drug development market.”

Mr. Vorwald has 25 years of experience in the global life science industry. Prior to joining the company, he served as senior vice president of commercial operations for Cytonome, Inc., a medical device company, where he was responsible for creating a global customer support division, sales policies and procedures and overseas market entry strategies. Prior to Cytonome, he served in numerous domestic and overseas management positions at Becton Dickinson’s Biosciences division, overseeing the company’s European, Asia-Pacific and Latin American markets. He has also worked for Guava Technologies and Delphi Corp. in business development capacities.